Clinical Trial Update: MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating three venetoclax-based regimens (Ven-Rd, Ven-Dd, Ven-DRd) in multiple myeloma. The study is currently recruiting at Mayo Clinic.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Darzalex (daratumumab) (daratumumab)
• Revlimid (lenalidomide) (lenalidomide)
• Venclexta (venetoclax) (venetoclax)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING